2024 / 06

Следующая статья
DOI: 10.24075/vrgmu.2024.060
Авторские права: © 2024 принадлежат авторам. Лицензиат: РНИМУ им. Н.И. Пирогова.
Статья размещена в открытом доступе и распространяется на условиях лицензии Creative Commons Attribution (CC BY).

ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ

Динамика маркеров воспаления на начальных стадиях хронической болезни почек при сахарном диабете 1-го типа

М. В. Осиков1,2, Л. А. Эфрос1,2, Л. Ю. Журавлева1,2, А. А. Федосов3
Информация об авторах

1 Южно-Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации, Челябинск, Россия

2 Челябинская областная клиническая больница, Челябинск, Россия

3 Российский университет дружбы народов имени Патриса Лумумбы, Москва, Россия

Для корреспонденции: Людмила Юрьевна Журавлева
ул. Воровского, 70 (Медгородок), корпус 8, 454048, г. Челябинск, Россия; ur.iam@0161_analim

Информация о статье

Вклад авторов: М. В. Осиков, Л. А. Эфрос — планирование исследования, разработка концепции и дизайна исследования, анализ литературы, интерпретация данных, подготовка черновика рукописи; Л. Ю. Журавлева — сбор данных, статистическая обработка, интерпретация данных, подготовка рукописи; А. А. Федосов — анализ литературы, интерпретация данных, подготовка рукописи.

Соблюдение этических стандартов: исследование одобрено этическим комитетом ФГБОУ ВО ЮУГМУ Минздрава России (протокол № 5 от 10 июня 2024 г.); проведено в соответствии со стандартами надлежащей клинической практики и принципами Хельсинкской декларации.

Статья получена: 24.10.2024 Статья принята к печати: 25.11.2024 Опубликовано online: 23.12.2024
|
  1. Дедов И. И., Шестакова М. В., Викулова О. К., Железнякова А. В., Исаков М. А., Сазонова Д. В., и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023; 26 (2): 104–23. DOI: 10.14341/DM13035.
  2. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102 (5S): S1–S127. DOI: 10.1016/j.kint.2022.06.008.
  3. Patidar K, Deng JH, Mitchell CS, Ford Versypt AN. Cross-Domain Text Mining of Pathophysiological Processes Associated with Diabetic Kidney Disease. Int J Mol Sci. 2024; 25(8): 4503. DOI: 10.3390/ijms25084503.
  4. Eckardt KU, Delgado C, Heerspink HJL, Pecoits-Filho R, Ricardo AC, Stengel B, et al. Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023; 104 (5): 888–903. DOI: 10.1016/j.kint.2023.05.013.
  5. Vyas DA, Eisenstein LG, Jones DS. Hidden in Plain Sight — Reconsidering the Use of Race Correction in Clinical Algorithms. N Engl J Med. 2020; 383 (9): 874–82. DOI: 10.1056/NEJMms2004740.
  6. Fan X, Yang M, Lang Y, Lu S, Kong Z, Gao Y, et al. Mitochondrial metabolic reprogramming in diabetic kidney disease. Cell Death Dis. 2024; 15: 442. DOI:10.1038/s41419-024-06833-0.
  7. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25 (12): 1822–32. DOI: 10.1038/s41591-019-0675-0. PubMed PMID: 31806905.
  8. Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, et al. Targeting inflammation to treat diabetic kidney disease: The road to 2030. Kidney Int. 2023; 103: 282–96. DOI: 10.1016/j.kint.2022.10.030.
  9. Varra FN, Varras M, Varra VK, Theodosis-Nobelos P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation-mediating treatment options (Review). Mol Med Rep. 2024; 29: 95. DOI: 10.3892/mmr.2024.13219.
  10. Xie R, Bishai DM, Lui DTW, Lee PCH, Yap DYH. Higher circulating neutrophil counts is associated with increased risk of all-cause mortality and cardiovascular disease in patients with diabetic kidney disease. Biomedicines. 2024; 12(8): 1907. DOI: 10.3390/biomedicines12081907. PubMed PMID: 39200371.
  11. Сахарный диабет 1 типа у взрослых: клинические рекомендации. Рубрикатор клинических рекомендаций [Электронный ресурс]. 2022 [дата доступа: 2024 октябрь 21]. Режим доступа: https://cr.minzdrav.gov.ru/recomend/286_2.
  12. Хроническая болезнь почек (ХБП): клинические рекомендации. Рубрикатор клинических рекомендаций [Электронный ресурс]. 2021 [дата доступа: 2024 октябрь 21]. Режим доступа: https://cr.minzdrav.gov.ru/schema/469_2.
  13. Островский В. К., Мащенко А. В., Янголенко Д. В. и др. Показатели крови и лейкоцитарного индекса интоксикации в оценке тяжести и определении прогноза при воспалительных, гнойных и гнойно-деструктивных заболеваниях. Клин. лаб. диагностика. 2006; 6: 50–3.
  14. Камышников В. С. Клинико-биохимическая лабораторная диагностика. Минск: Изд-во «Интерпрессервис», 2003; 495 с.
  15. Tonneijck L, Muskiet MH, Smits MM, van Bommel EJ, Heerspink HJ, van Raalte DH, Joles JA. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J Am Soc Nephrol. 2017; 28 (4): 1023–39. DOI: 10.1681/ASN.2016060666.
  16. Kanbay M, Copur S, Guldan M, Ozbek L, Hatipoglu A, Covic A, Mallamaci F, Zoccali C. Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states. Clin Kidney J. 2024; 17 (7): sfae195. DOI: 10.1093/ckj/sfae195.
  17. Jin L, Wang X, Liu Y, Xiang Q, Huang R. High levels of blood glycemic indicators are associated with chronic kidney disease prevalence in non-diabetic adults: Cross-sectional data from the national health and nutrition examination survey 2005–2016. J Clin Transl Endocrinol. 2024; 36: 100347. DOI: 10.1016/j.jcte.2024.100347.
  18. Rayego-Mateos S, Morgado-Pascual JL, Opazo-Ríos L, Guerrero-Hue M, Garcia-Caballero C, Vazquez-Carballo C, et al. Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. Int J Mol Sci. 2020; 21 (11): 3798. DOI: 10.3390/ijms21113798.
  19. Shirakawa K, Sano M. Neutrophils and neutrophil extracellular traps in cardiovascular disease: an overview and potential therapeutic approaches. Biomedicines. 2022; 10: 1850. DOI: 10.3390/biomedicines10081850.
  20. Zhang R, Chen J, Xiong Y, Wang L, Huang X, Sun T, et al. Increased neutrophil count Is associated with the development of chronic kidney disease in patients with diabetes. J Diabetes. 2022; 14: 442–54. DOI: 10.1111/1753-0407.13292.
  21. Zeng G, Lin Y, Xie P, Lin J, He Y, Wei J. Relationship of the Neutrophil-Lymphocyte Ratio with All-Cause and Cardiovascular Mortality in Patients with Diabetic Kidney Disease: A Prospective Cohort Study of NHANES Study. J Multidiscip Healthc. 2024; 17: 2461–73. DOI: 10.2147/JMDH.S465317. PubMed PMID: 38799017.
  22. Wan H, Wang Y, Fang S, Chen Y, Zhang W, Xia F, et al. Associations between the neutrophil-to-lymphocyte ratio and diabetic complications in adults with dabetes: a cross-sectional study. J Diabetes Res. 2020; 2020: 1–9. DOI: 10.1155/2020/6219545
  23. Gao JL, Shen J, Yang LP, Liu L, Zhao K, Pan XR, et al. Neutrophil-to-lymphocyte ratio associated with renal function in type 2 diabetic patients. World J Clin Cases. 2024; 12 (14): 2308–15. DOI: 10.12998/wjcc.v12.i14.2308. PubMed PMID: 38765748.
  24. Ko HL, Jung J, Lee J, Lim JH, Im DW, Kim YC, et al. Dynamic nature and prognostic value of the neutrophil-to-lymphocyte ratio in critically ill patients with acute kidney injury on continuous renal replacement therapy: A multicenter cohort study. Front Med (Lausanne). 2023; 10: 1162381. DOI: 10.3389/fmed.2023.1162381.
  25. Karava V, Kondou A, Dotis J, Taparkou A, Farmaki E, Kollios K, et al. Exploring systemic inflammation in children with chronic kidney disease: correlates of interleukin 6. Pediatr Nephrol. 2024; 39: 1567–76. DOI:10.1007/s00467-023-06234-z.
  26. Liu J, Liu X, Li Y, Quan J, Wei S, An S, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. Biosci Rep. 2018; 38: 2–19. DOI: 10.1042/BSR20180172.
  27. Lau LFS, Ng JK, Fung WWS, Chan GCK, Mei-Shan Cheng, Chow KM, et al. Relationship between serial serum neutrophil-lymphocyte ratio, cardiovascular mortality, and all-cause mortality in Chinese peritoneal dialysis patients. Kidney Blood Press Res. 2023; 48 (1): 414–23. DOI: 10.1159/000530554
  28. Messias BA, Botelho RV, Saad SS, Mocchetti ER, Turke KC, Waisberg J. Serum C-reactive protein is a useful marker to exclude anastomotic leakage after colorectal surgery. Sci Rep. 2020; 10 (1): 1687. DOI: 10.1038/s41598-020-58780-3.
  29. Zhang L, Li W, Gong M, Zhang Z, Xue X, Mao J et al. C-reactive protein inhibits C3a/C3aR-dependent podocyte autophagy in favor of diabetic kidney disease. FASEB J. 2022; 36(6): e22332. DOI: 10.1096/fj.202200198R. PubMed PMID: 35503088.
  30. Wang Y, Guo J, Shao B, Chen H, Lan H. The Role of TGF-β1/ SMAD in diabetic nephropathy: mechanisms and research development. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023; 54 (6): 1065–73. Chinese. DOI: 10.12182/20231160108. PubMed PMID: 38162063.
  31. Zhang L, Shen ZY, Wang K, Li W, Shi JM, Osoro EK, et al. C-reactive protein exacerbates epithelial-mesenchymal transition through Wnt/β-catenin and ERK signaling in streptozocin-induced diabetic nephropathy. FASEB J. 2019; 33 (5): 6551–63. DOI: 10.1096/fj.201801865RR. PubMed PMID: 30794428.
  32. Li J, Chen J, Lan HY, Tang Y. Role of C-Reactive protein in Kidney Diseases. Kidney Dis (Basel). 2022; 9 (2): 73–81. DOI: 10.1159/000528693. PubMed PMID: 37065607.
  33. Geng T, Zhu K, Lu Q, Wan Z, Chen X, Liu L, et al. Healthy lifestyle behaviors, mediating biomarkers, and risk of microvascular complications among individuals with type 2 diabetes: A cohort study. PLoS Med. 2023; 20 (1): e1004135. DOI: 10.1371/journal.pmed.1004135. PubMed PMID: 36626356.
  34. Tang M, Cao H, Wei XH, Zhen Q, Liu F, Wang YF, et al. Association between high-sensitivity C-Reactive protein and Diabetic Kidney Disease in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022; 13: 885516. DOI: 10.3389/fendo.2022.885516. PubMed PMID: 35784528.
  35. Lin CC, Li CI, Liu CS, Liao LN, Yang CW, Lin CH, et al. Association of high-sensitivity C-reactive protein and diabetic nephropathy in patients with type 2 diabetes: a Mendelian randomization study. BMJ Open Diabetes Res Care. 2023; 11 (1): e003197. DOI: 10.1136/bmjdrc-2022-003197. PubMed PMID: 36828641.
  36. Aktas G. Serum C-reactive protein to albumin ratio as a reliable marker of diabetic neuropathy in type 2 diabetes mellitus. Biomol Biomed. 2024; 24 (5): 1380–6. DOI: 10.17305/bb.2024.10426. PubMed PMID: 38635449.
  37. Kumari S, Singh B. Assessment of correlation of serum high-sensitive C-Reactive protein, urinary albumin-to-creatinine ratio, and lipid profile in diabetics. J Pharm Bioallied Sci. 2021; 13 (2): S1569–S1572. DOI: 10.4103/jpbs.jpbs_290_21. PubMed PMID: 35018031.
  38. Al-Bayati MA, Jamil DA, Al-Aubaidy HA. Cardiovascular effects of copper deficiency on activity of superoxide dismutase in diabetic nephropathy. N Am J Med Sci. 2015; 7(2): 41–6.
  39. Lee MJ, Jung CH, Kang YM, Jang JE, Leem J, Park JY, et al. Serum ceruloplasmin level as a predictor for the progression of diabetic nephropathy in korean men with type 2 diabetes mellitus. Diabetes Metab J. 2015; 39 (3): 230–9. DOI: 10.4093/dmj.2015.39.3.230. PubMed PMID: 26124993.
  40. de Paula Silva L, de Moraes Rego FG, Picheth G, Müller-Santos M, Alberton D. Prospection of plasma proteins as biomarkers for diabetes mellitus monitoring. J Diabetes Metab Disord. 2021; 20 (1): 611–20. DOI: 10.1007/s40200-021-00788-1. PubMed PMID: 34222081.
  41. Wang S, Lu Z, Wang Y, Zhang T, He X. Metalloproteins and apolipoprotein C: candidate plasma biomarkers of T2DM screened by comparative proteomics and lipidomics in ZDF rats. Nutr Metab (Lond). 2020; 17: 66. DOI: 10.1186/s12986-020-00488-2. PubMed PMID: 32817751.
  42. Swaminathan SM, Rao IR, Shenoy SV, Prabhu AR, Mohan PB, Rangaswamy D, et al. Novel biomarkers for prognosticating diabetic kidney disease progression. Int Urol Nephrol. 2023; 55 (4): 913–28. DOI: 10.1007/s11255-022-03354-7. PubMed PMID: 36271990.
  43. Jung CY, Yoo TH. Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease. Diabetes Metab J. 2022; 46 (2): 181–97. DOI: 10.4093/dmj.2021.0329.